Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer.
adrenocortical carcinoma
biomarker
circulating microRNA
early prognosis
miR-483-5p
recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Mar 2020
19 Mar 2020
Historique:
received:
23
01
2020
revised:
12
03
2020
accepted:
18
03
2020
entrez:
25
3
2020
pubmed:
25
3
2020
medline:
25
3
2020
Statut:
epublish
Résumé
We have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at least 3 years; NR3yrs) from patients with poor prognosis (recurrence or death within 3 years after surgery; R < 3yrs). We conducted a single-center retrospective analysis using sera from 48 patients with ACC that were initially non-metastatic and treated by surgery. Sera sampled within 3 months after surgery were available in 26 patients. MiR-483-5p absolute circulating levels were measured using quantitative PCR. Thirteen patients showed a recurrence before 3 years (=R < 3yrs). Thirteen patients showed no recurrence within 3 years, including 11 patients with a follow-up longer than 3 years (=NR3yrs). Serum miR-483-5p levels were higher in R < 3yrs than in NR3yrs: 1,541,990 ± 428,377 copies/mL vs. 388,457 ± 62,169 copies/mL (
Identifiants
pubmed: 32204444
pii: cancers12030724
doi: 10.3390/cancers12030724
pmc: PMC7140036
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Institut National Du Cancer
ID : PRT-K14-079
Organisme : Ligue Contre le Cancer
ID : R16167CC
Organisme : Ligue Contre le Cancer
ID : R19013CC
Organisme : Else Kröner-Fresenius-Stiftung
ID : 2016_A96
Organisme : Deutsche Forschungsgemeinschaft
ID : 314061271 (CRC/TRR 205)
Références
Nat Genet. 2014 Jun;46(6):607-12
pubmed: 24747642
Eur J Endocrinol. 2018 May;178(5):R215-R230
pubmed: 29475877
Lab Invest. 2014 Mar;94(3):331-9
pubmed: 24336071
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Endocr Relat Cancer. 2011 Oct 27;18(6):643-55
pubmed: 21859927
Cancer. 2009 Jan 15;115(2):243-50
pubmed: 19025987
Cancer. 2011 Apr 15;117(8):1630-9
pubmed: 21472710
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Front Endocrinol (Lausanne). 2016 Jan 20;6:195
pubmed: 26834703
Oncotarget. 2017 Jul 10;8(39):65525-65533
pubmed: 29029450
Endocr Relat Cancer. 2013 Jul 05;20(4):579-94
pubmed: 23756429
Sci Rep. 2017 Jul 14;7(1):5474
pubmed: 28710381
Int J Cancer. 2018 Aug 15;143(4):944-957
pubmed: 29516499
Endocr Rev. 2014 Apr;35(2):282-326
pubmed: 24423978
Surgery. 2013 Dec;154(6):1224-8; discussion 1229
pubmed: 24238045
Clin Cancer Res. 2009 Dec 15;15(24):7684-7692
pubmed: 19996210
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Eur J Cancer. 2010 Mar;46(4):713-9
pubmed: 20044246